- Home
- NWG vs ARGX Comparison
NWG vs ARGX Comparison
Compare NWG & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWG
- ARGX
- Stock Information
- Founded
- NWG 1727
- ARGX 2008
- Country
- NWG United Kingdom
- ARGX Netherlands
- Employees
- NWG N/A
- ARGX N/A
- Industry
- NWG Commercial Banks
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NWG Finance
- ARGX Health Care
- Exchange
- NWG Nasdaq
- ARGX Nasdaq
- Market Cap
- NWG 62.0B
- ARGX 51.1B
- IPO Year
- NWG N/A
- ARGX 2017
- Fundamental
- Price
- NWG $15.28
- ARGX $911.49
- Analyst Decision
- NWG
- ARGX Strong Buy
- Analyst Count
- NWG 0
- ARGX 16
- Target Price
- NWG N/A
- ARGX $910.63
- AVG Volume (30 Days)
- NWG 2.9M
- ARGX 366.1K
- Earning Date
- NWG 10-24-2025
- ARGX 10-30-2025
- Dividend Yield
- NWG 4.17%
- ARGX N/A
- EPS Growth
- NWG 25.82
- ARGX N/A
- EPS
- NWG 0.88
- ARGX 23.27
- Revenue
- NWG $20,890,125,543.00
- ARGX $3,683,281,000.00
- Revenue This Year
- NWG $17.03
- ARGX $85.93
- Revenue Next Year
- NWG $6.45
- ARGX $35.17
- P/E Ratio
- NWG $8.47
- ARGX $36.74
- Revenue Growth
- NWG 11.06
- ARGX 92.98
- 52 Week Low
- NWG $9.16
- ARGX $510.06
- 52 Week High
- NWG $16.52
- ARGX $934.13
- Technical
- Relative Strength Index (RSI)
- NWG 48.07
- ARGX 68.36
- Support Level
- NWG $14.85
- ARGX $908.16
- Resistance Level
- NWG $16.52
- ARGX $932.29
- Average True Range (ATR)
- NWG 0.24
- ARGX 20.40
- MACD
- NWG -0.14
- ARGX 1.32
- Stochastic Oscillator
- NWG 24.18
- ARGX 78.05
About NWG NatWest Group plc (each representing two (2))
NatWest Group derives around 90% of its total income from the United Kingdom. The bank operates a retail, commercial, and private bank in the UK, offering clients lending and payment services as well as asset management services.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.